Biodesix Closes on $20M Series D Round

The funds will go toward commercialization of its VeriStrat test for non-small cell lung cancer and to support collaborations with biotechnology and pharmaceutical firms to develop companion diagnostics.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories